Your browser doesn't support javascript.
loading
Unveiling Synergistic Potency: Exploring Butyrolactone I to Enhance Gentamicin Efficacy against Methicillin-Resistant Staphylococcus aureus (MRSA) Strain USA300.
Jiang, Hanxiang; Chen, Jiaqin; Du, Xinyang; Feng, Dong; Zhang, Yanjun; Qi, Jiangfeng; He, Yajing; An, Zhilong; Lu, Yuanyuan; Ge, Chun; Wang, Ying.
Afiliação
  • Jiang H; School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
  • Chen J; School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
  • Du X; School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
  • Feng D; Nanjing Southern Pharmaceutical Technology Co., Ltd., Nanjing 211100, China.
  • Zhang Y; School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
  • Qi J; School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
  • He Y; School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
  • An Z; Nanjing Southern Pharmaceutical Technology Co., Ltd., Nanjing 211100, China.
  • Lu Y; School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
  • Ge C; Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
  • Wang Y; Department of Clinical Pharmacy, School of Basic Medicine & Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
ACS Infect Dis ; 10(1): 196-214, 2024 01 12.
Article em En | MEDLINE | ID: mdl-38127778
ABSTRACT
Staphylococcus aureus, including MRSA strains, poses significant health risks, imposing a significant disease burden and mortality. We investigate butyrolactone I (BL-1), a marine-derived metabolite from Aspergillus terreus, enhancing aminoglycoside efficacy against MRSA. A promising synergy is observed with BL-1 and various aminoglycosides, marked by low fractional inhibitory concentration indexes (FICIs < 0.5). Comprehensive studies utilizing USA300 MRSA and gentamicin reveal a remarkable one-fourth reduction in minimum inhibitory concentration (MIC) with 20 µg/mL BL-1. A relative abundance assay indicates that BL-1 enhances gentamicin uptake while restraining extracellular presence, involving intricate transmembrane signaling and molecular interactions. RNA-Seq analysis yielded an unexpected revelation, unveiling a distinctive gene expression profile and distinguishing it from other treatment approaches. Furthermore, meticulous analyses validated the extensive perturbations induced by BL-1 exposure, affecting diverse biological functions, encompassing glycolysis, amino acid metabolisms, substance transmembrane transport, and virulence generation. These valuable insights inspired further confirmation of bacterial virulence and the modulation of membrane permeability resulting from BL-1 treatment. Phenotypic validations corroborated our observations, revealing reduced membrane permeability and hemolytic toxicity, albeit demanding a deeper comprehension of the intricate interplay underlying these actions. Our study contributes crucial mechanistic insights to the development of therapeutic strategies against this notorious pathogen and the judicious employment of aminoglycosides. Additionally, it elucidates marine-derived metabolites' ecological and functional roles, exemplified by fungal quorum sensing signals. These compounds could give producers a competitive edge, inhibiting microorganism proliferation and suggesting novel approaches for combating resistant pathogens.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: 4-Butirolactona / Staphylococcus aureus Resistente à Meticilina Idioma: En Revista: ACS Infect Dis Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: 4-Butirolactona / Staphylococcus aureus Resistente à Meticilina Idioma: En Revista: ACS Infect Dis Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China